1h fa
IRWD Jumps Over 30% Premarket on January 2, 2026 as Guidance Beats Street
On Friday, January 2, 2026, Ironwood Pharmaceuticals (NASDAQ: IRWD) surged about 36% in premarket trading after issuing 2026 guidance above Wall Street expectations. The outlook includes total revenue of $450–475 million and adjusted EBITDA above $300 million, supported by LINZESS U.S. net sales of $1.125–1.175 billion and a list price cut effective January 1, 2026.